Accelerate Accounts Payable vs Capital Surpluse Analysis
AXDX Stock | USD 0.92 0.02 2.13% |
Accelerate Diagnostics financial indicator trend analysis is way more than just evaluating Accelerate Diagnostics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Accelerate Diagnostics is a good investment. Please check the relationship between Accelerate Diagnostics Accounts Payable and its Capital Surpluse accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Accelerate Diagnostics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Accelerate Stock please use our How to Invest in Accelerate Diagnostics guide.
Accounts Payable vs Capital Surpluse
Accounts Payable vs Capital Surpluse Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Accelerate Diagnostics Accounts Payable account and Capital Surpluse. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Accelerate Diagnostics' Accounts Payable and Capital Surpluse is 0.83. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Capital Surpluse in the same time period over historical financial statements of Accelerate Diagnostics, assuming nothing else is changed. The correlation between historical values of Accelerate Diagnostics' Accounts Payable and Capital Surpluse is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Accelerate Diagnostics are associated (or correlated) with its Capital Surpluse. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Surpluse has no effect on the direction of Accounts Payable i.e., Accelerate Diagnostics' Accounts Payable and Capital Surpluse go up and down completely randomly.
Correlation Coefficient | 0.83 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Accounts Payable
An accounting item on the balance sheet that represents Accelerate Diagnostics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Accelerate Diagnostics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Capital Surpluse
Most indicators from Accelerate Diagnostics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Accelerate Diagnostics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Accelerate Diagnostics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Accelerate Stock please use our How to Invest in Accelerate Diagnostics guide.At this time, Accelerate Diagnostics' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 219.4 K in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 3.8 M in 2024.
2023 | 2024 (projected) | Interest Income | 1.3M | 1.2M | Non Recurring | 2.7K | 2.4K |
Accelerate Diagnostics fundamental ratios Correlations
Click cells to compare fundamentals
Accelerate Diagnostics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Accelerate Diagnostics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 134.4M | 93.4M | 83.0M | 65.0M | 31.4M | 48.2M | |
Other Current Liab | 5.1M | 4.3M | 3.8M | 3.2M | 3.4M | 3.6M | |
Total Current Liabilities | 8.2M | 7.0M | 6.9M | 66.6M | 12.0M | 12.6M | |
Total Stockholder Equity | (7.4M) | (62.8M) | (35.1M) | (22.3M) | (19.9M) | (18.9M) | |
Property Plant And Equipment Net | 11.8M | 9.3M | 7.9M | 7.8M | 5.1M | 2.7M | |
Net Debt | 73.1M | 114.2M | 71.2M | 42.6M | 27.1M | 28.4M | |
Retained Earnings | (414.7M) | (493.0M) | (570.7M) | (607.2M) | (668.9M) | (635.4M) | |
Accounts Payable | 2.4M | 1.3M | 2.0M | 4.5M | 4.8M | 5.0M | |
Cash | 61.0M | 35.8M | 39.9M | 34.9M | 12.1M | 23.7M | |
Non Current Assets Total | 12.6M | 11.4M | 9.7M | 9.0M | 6.9M | 5.4M | |
Non Currrent Assets Other | 750K | (5.9M) | 1.8M | 1.2M | 1.8M | 1.9M | |
Cash And Short Term Investments | 108.5M | 68.3M | 63.6M | 45.6M | 13.2M | 12.6M | |
Net Receivables | 3.2M | 1.6M | 2.3M | 2.4M | 2.6M | 2.8M | |
Common Stock Shares Outstanding | 5.4M | 5.5M | 5.6M | 6.2M | 12.5M | 13.1M | |
Liabilities And Stockholders Equity | 134.4M | 93.4M | 83.0M | 65.0M | 31.4M | 48.2M | |
Non Current Liabilities Total | 133.6M | 149.3M | 111.2M | 20.7M | 39.2M | 23.3M | |
Other Current Assets | 1.2M | 1.8M | 1.6M | 2.0M | 5.3M | 5.6M | |
Other Stockholder Equity | 407.3M | 430.0M | 535.6M | 585.3M | 649.6M | 682.0M | |
Total Liab | 141.8M | 156.2M | 118.1M | 87.3M | 51.3M | 28.6M | |
Property Plant And Equipment Gross | 11.8M | 9.3M | 7.9M | 7.8M | 16.1M | 16.9M | |
Total Current Assets | 121.9M | 82.0M | 73.3M | 56.0M | 24.5M | 42.8M | |
Accumulated Other Comprehensive Income | (58K) | 91K | (60K) | (400K) | (612K) | (581.4K) | |
Common Stock Total Equity | 56K | 54K | 55K | 58K | 52.2K | 49.6K | |
Common Stock | 55K | 58K | 68K | 97K | 14K | 13.3K | |
Current Deferred Revenue | 271K | 376K | 451K | 547K | 1.5M | 1.6M | |
Other Liab | 19K | 335K | 808K | 1.5M | 1.4M | 1.5M | |
Other Assets | 750K | 5.3M | 1.8M | 1.2M | 1.0 | 0.95 | |
Property Plant Equipment | 7.9M | 6.1M | 7.9M | 7.8M | 8.9M | 9.4M | |
Inventory | 8.1M | 9.2M | 5.1M | 5.2M | 3.3M | 2.7M | |
Net Tangible Assets | (7.4M) | (62.8M) | (35.1M) | (22.3M) | (20.0M) | (19.0M) | |
Long Term Debt | 130.0M | 145.9M | 108.0M | 16.9M | 36.1M | 51.1M | |
Retained Earnings Total Equity | (330.3M) | (414.7M) | (493.0M) | (570.7M) | (513.6M) | (487.9M) | |
Short Term Investments | 47.4M | 32.5M | 23.7M | 10.7M | 1.1M | 1.0M | |
Capital Surpluse | 432.9M | 452.3M | 475.1M | 580.7M | 667.7M | 701.1M | |
Non Current Liabilities Other | 3.6M | 3.4M | 3.2M | 874K | 1.2M | 1.6M | |
Short Long Term Debt Total | 134.1M | 150.0M | 111.1M | 77.5M | 39.2M | 37.3M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Accelerate Diagnostics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Accelerate Diagnostics' short interest history, or implied volatility extrapolated from Accelerate Diagnostics options trading.
Pair Trading with Accelerate Diagnostics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Accelerate Diagnostics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Accelerate Diagnostics will appreciate offsetting losses from the drop in the long position's value.Moving against Accelerate Stock
0.69 | FLGC | Flora Growth Corp Financial Report 20th of May 2024 | PairCorr |
0.58 | CGC | Canopy Growth Corp Financial Report 27th of June 2024 | PairCorr |
0.45 | ERNA | Eterna Therapeutics | PairCorr |
0.43 | MLECW | Moolec Science SA | PairCorr |
0.41 | FHTX | Foghorn TherapeuticsInc Financial Report 13th of May 2024 | PairCorr |
The ability to find closely correlated positions to Accelerate Diagnostics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Accelerate Diagnostics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Accelerate Diagnostics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Accelerate Diagnostics to buy it.
The correlation of Accelerate Diagnostics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Accelerate Diagnostics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Accelerate Diagnostics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Accelerate Diagnostics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Accelerate Diagnostics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Accelerate Stock please use our How to Invest in Accelerate Diagnostics guide.Note that the Accelerate Diagnostics information on this page should be used as a complementary analysis to other Accelerate Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for Accelerate Stock analysis
When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Transaction History View history of all your transactions and understand their impact on performance | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |
Is Accelerate Diagnostics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Accelerate Diagnostics. If investors know Accelerate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Accelerate Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.94) | Revenue Per Share 0.966 | Quarterly Revenue Growth 0.019 | Return On Assets (0.70) |
The market value of Accelerate Diagnostics is measured differently than its book value, which is the value of Accelerate that is recorded on the company's balance sheet. Investors also form their own opinion of Accelerate Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Accelerate Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Accelerate Diagnostics' market value can be influenced by many factors that don't directly affect Accelerate Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Accelerate Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Accelerate Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Accelerate Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.